PipelineReview.com5h
Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar
RALEIGH, NC, USA I 10, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas ...
PipelineReview.com5h
AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
BRISBANE, Australia & INDIANAPOLIS, IN, USA I 10, 2025 I AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha ...
PipelineReview.com5h
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
INGELHEIM, Germany I 10, 2025 I Boehringer Ingelheim announced today that the FIBRONEER™-ILD trial met its primary endpoint, which was the ...
PipelineReview.com5h
Orca Bio’s Orca-T® Meets Primary Endpoint in the Pivotal Precision-T Phase 3 Clinical Study for Hematologic Malignancies
Orca Bio to present efficacy and safety data with Orca-T compared to conventional allogeneic hematopoietic stem cell transplant (alloHSCT) at the 51st Annual ...
PipelineReview.com5h
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
PASADENA, CA, USA I 10 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement ...
PipelineReview.com5h
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
OLX75016: A GWAS-derived therapeutic targeting MASH, liver fibrosis, and other cardiometabolic indications SEONGNAM, South Korea I 10, 2025 I OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading ...
PipelineReview.com11h
BioRay’s ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
SHANGHAI, China I 10, 2025 I On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products ...
PipelineReview.com11h
Bayer files for approval of extended 6-month treatment interval for Eylea™ 8 mg in the EU
Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...
PipelineReview.com11h
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
NEW TAIPEI CITY, Taiwan I February 9, 2025 I Caliway Biopharmaceuticals (TWSE-6919) announced today that CBL-514's second Phase 2b clinical study (CBL-0205), ...
PipelineReview.com2d
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
CHENGDU, China I 8, 2025 I Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has ...
PipelineReview.com5d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) – ...